Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Aim(s): To demonstrate the efficacy of medical therapy with SSA and PRRT in patients with well- and moderately differentiated neuroendocrine tumors.
Materials and methods: We evaluated 55 patients with well- or moderately differentiated neuroendocrine tumors; 31 patients with either metastatic, unresectable or functioning tumors were treated with SSA. Ten of them with metastatic disease or unresectable tumors, all with increased uptake on Octreoscan, underwent PRRT with 90Y or 177Lu.
Conference: 8th Annual ENETSConcerence (2011)
To read the full abstract, please log into your ENETS Member account.